Asarina Pharma Q4’20: First Comment
Research Note
2021-02-25
11:26
In Asarina Pharma’s Q4’20 report, we are encouraged to see cost measures taken to readout two phase 2 studies: menstrual migraine (MM) and Tourette’s Syndrome (Tourettes), with the current cash position. The top-line results in MM move nearer, and we see an increasing rationale with sepranolone in Tourettes. In other words, interesting times ahead.
AH
Anders Hedlund
Disclosures and disclaimers